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Renoprotective action of statin
estimated from mapping renal
failure in Japan
To the Editor: We have demonstrated [1, 2] the re-
markable regional difference in the incidence of end-
stage renal disease (ESRD) within Japan, which has an
ethnically homogenous population, suggesting the pres-
ence of factors other than genetics, which may contribute
to the difference. Renoprotective actions of statins, re-
cently proposed [3], were estimated by correlating two
maps of ESRD incidence and the amount of expenses
prescribed on statins in Japan. Annually, the Japanese
Society for Dialysis Therapy reports the numbers of pa-
tients entering maintenance dialysis in each prefecture of
Japan [4]. We used the findings for 1996 to 2000 to corre-
late the regional ESRD distribution with regional differ-
ences in annual amounts paid for antihypertensive drugs
and statins during the same 5 years (Crecon Research
& Consulting, Inc., Tokyo, Japan) (Table 1). Multiple re-
gression analysis identified converting enzyme inhibitor
(F = 34.3) and statins (F = 7.1) as independently negative
factors arresting the progression of nephropathies, while
total antihypertensives as positive factors (F = 17.8). Re-
nal protective actions of statins, in addition to converting
enzyme inhibitors, those of which we already reported [2],
were revealed by analyzing ESRD map. Our epidemio-
logic approaches for Japan as a whole seemed useful to
estimate the renoprotective actions of certain agents that
have not been clarified by large-scale clinical trials.
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Table 1. Regional differences in annual incidence of ESRD and
usage of stain (1996 to 2000)
ESRD incidencea Usage of statina
Region million/year yen/person/year
1. Hokkaido 257 ± 5 2510 ± 120
2. Tohoku 222 ± 5 2090 ± 71
3. Kanto 230 ± 5 1760 ± 80
4. Koshinetsu 221 ± 10 1780 ± 90
5. Hokuriku 213 ± 7 2430 ± 90
6. Tokai 235 ± 6 1820 ± 80
7. Kinki 243 ± 7 2040 ± 70
8. Chyugoku 228 ± 7 2110 ± 100
9. Shikoku 267 ± 8 2090 ± 60
10. Kyushu 268 ± 5 1840 ± 70
11. Okinawa 284 ± 5 1090 ± 60
Regions are from north (1, Hokkaido) to south (11, Okinawa). Mean ± SEM.





To the Editor: A recent study by Ram et al [1] criticizes
earlier randomized, controlled trials on their statistical
validity, but itself exhibits major statistical flaws.
The authors in [1] criticize others [2] for having a
“surveillance group [that] had more prior interventions
than the control group.” Yet in their own study, it ap-
pears that the entry percutaneous transluminal angio-
plasty (PTA) rate in the control group was 2.5 times
higher than the flow group (Table 1, row 2).
The authors in [1] also criticize others [3] for having a
“group [that] had a high thrombosis rate because of mul-
tiple thromboses in a small number of grafts.” Yet the au-
thors admit to this very shortcoming for their flow group,
and explain that its high thrombosis rate “is misleading
in that it was caused by multiple thromboses in three
grafts.” The poor comparability between their groups is
even more pronounced when assessing entry graft age
(Ram et al [1], Table 2) where removing not three, but
one graft from the control group makes it 9.6 months
younger (P = 0.043) than the flow group! These dispari-
ties suggest a lack of uniformity among the three groups
on the very issues being studied: PTA rate, thrombotic
events (Table 1, Row 1), and graft survival (age).
The lack of group uniformity for these crucial param-
eters is a consequence of the small number of patients
inadequate for the high values of variation coefficient ra-
tio of standard deviation to mean value (S/M) (Table 1,
rows 3 and 4). To achieve credible data, Bland [4] suggests
that authors should choose the number of patients based
